Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach;   Lymphoma;   Sarcoma;   Cutaneous T Cell Lymphoma;   Head and Neck Squamous Cell Carcinoma;   Basal Cell Carcinoma;   Cutaneous T-cell Lymphoma;   Cutaneous Squamous Cell Carcinoma
Interventions:   Drug: GZ17-6.02;   Drug: Capecitabine
Sponsors:   Genzada Pharmaceuticals USA, Inc.;   Translational Drug Development
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 19, 2022 / by / in
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Condition:   NSCLC
Interventions:   Drug: Poziotinib;   Drug: Docetaxel
Sponsor:   Spectrum Pharmaceuticals, Inc
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 19, 2022 / by / in
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Condition:   HER2-positive Breast Cancer
Interventions:   Biological: Dendritic Cell (DC1) Vaccine;   Drug: Trastuzumab;   Drug: Pepinemab;   Biological: T-Cell therapy
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Vaccinex Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 19, 2022 / by / in
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
Condition:   Enteric Hyperoxaluria
Interventions:   Drug: SYNB8802v1;   Other: Placebo
Sponsor:   Synlogic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2022 / by / in
Promoting Informed Choice for Breast Cancer Screening
Condition:   Breast Cancer
Intervention:   Behavioral: Survey
Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2022 / by / in
ALM-488 for Intra-Operative Visualization of Nerves in Head and Neck Surgery
Condition:   Surgery
Interventions:   Drug: ALM-488;   Other: Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay;   Other: Intra-operative Visualization using White Light Reflectance (WLR)
Sponsors:   Alume Biosciences, Inc.;   Ergomed
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2022 / by / in
Be-Active Study – Increasing Physical Activity in Cancer Survivors
Conditions:   Physical Activity;   Exercise;   Cancer Survivors
Interventions:   Behavioral: Behavioral Internet program;   Behavioral: Informational newsletter condition
Sponsors:   The Miriam Hospital;   Brown University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2022 / by / in
MarginProbe 2.0 Data Collection Protocol
Condition:   Breast Cancer
Intervention:   Device: MarginProbe2.0
Sponsor:   Dilon Medical Technologies Ltd.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2022 / by / in
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Conditions:   Gastrostomy;   Gastric;   GastroEsophageal Cancer
Interventions:   Other: Standard of Care;   Other: Control Group
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 17, 2022 / by / in
A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Conditions:   Non Small Cell Lung Cancer;   Solid Tumor
Intervention:   Drug: BBP-398 with nivolumab
Sponsors:   Navire Pharma Inc., a BridgeBio company;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 17, 2022 / by / in